Demarzo MG, Bodini G, Vanello M, Martini M, et al. Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Aliment Pharmacol Ther 2021;53:1044-1045.
PMID: 33831237